The low-affinity use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke

Annals of the New York Academy of Sciences

Volumn 890, Issue , 1999, Pages 406-420

  Palmer, Gene C ^a   Cregan, Edward F ^a   Bialobok, Paul ^a   Sydserff, Simon G ^a   Hudzik, Thomas J ^a   McCarthy, Dennis J ^a  

^a Astra Arcus USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BUDIPINE; DIZOCILPINE; EXCITATORY AMINO ACID; FPL 15853; LANICEMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; RECEPTOR SUBUNIT; REMACEMIDE; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONFERENCE PAPER; DRUG SAFETY; EPILEPSY; HEAD INJURY; HEADACHE; HUMAN; NERVE DEGENERATION; NERVE STIMULATION; NEUROPROTECTION; NONHUMAN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; STROKE; VERTIGO; VISUAL DISORDER;

EID: 0033403301     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb08020.x     Document Type: Conference Paper

References (42)

1. 1. Olney, J.W. 1978. Neurotoxicity of excitatory amino acids. In Kainic Acid as a Tool in Neurobiology. E.G. McGeer, J.W. Olney & P.L. McGeer, Eds.: 37-70. Raven Press. New York.
2. 2. Buchan, A.M. 1990. Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted? Cerebrovasc. Brain Metab. Rev. 2: 1-26.
3. 3. Chapman, A.G., J.H. Swann et al. 1990. Cerebroprotective and anticonvulsant action of competitive and non-competitive NMDA antagonists. In Amino Acids: Chemistry, Biology and Medicine. G. Lubec & G.A. Rosenthal, Eds.: 219-232. Escom Publishers. Amsterdam.
4. 4. Gee, K.R. 1994. Therapeutic potential of PCP receptor ligands. Exp. Opin. Invest. Drugs 3: 1021-1030.
5. 5. Collins, R.C., B.H. Dobkin et al. 1989. Selective vulnerability of the brain: new insights into the pathophysiology of stroke. Ann. Int. Med. 110: 992-1000.
6. 6. Rogawski, M.A. 1993. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. 14: 325-331.
7. 7. Grant, K.A., G. Colombo et al. 1996. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35: 1709-1719.
8. 8. Palmer, G.C. & J.B. Hutchison. 1997. Preclinical and clinical aspects of remacemide hydrochloride. In Excitatory Amino Acids-Clinical Results with Antagonists. P. Herrling, Ed.: 109-120. Academic Press. New York.
9. 9. Mueller, A.L. 1998. Preclinical neruoprotectant efficacy of NPS 1506, a novel NMDA receptor antagonist. In Glutamate Pharmacology Therapeutic Implications. International Business Communications. Southborough, MA.
10. 10. Palmer, G.C., J.A. Miller et al. 1997. Low affinity NMDA receptor antagonists, the neuroprotective potential of ARL 15896AR. Ann. N.Y. Acad. Sci. 825: 220-231.
11. 11. Shohami, E., R. Gallily et al. 1997. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211), a neuroprotective agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. 35: 361-365.
12. 12. Palmer, G.C., R.J. Murray et al. 1999. [S]-AR-R 15896AR, a novel anticonvulsant: acute safety, pharmacokinetic, and pharmacodynamic properties. J. Pharmacol. Exp. Ther. 288: 121-132.
13. 13. Hudzik, T.J., L. Freedman et al. 1996. Remacemide hydrochloride and ARL 15896AR lack abuse potential: additional differences from other uncompetitive NMDA antagonists. Epilepsia 37: 544-550.
14. 14. Hudzik, T.J. & G.C. Palmer. 1995. Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Epilepsy Res. 21: 183-193.
15. 15. Widzowski, D., P. Bialobok et al. 1997. Low affinity non-competitive (LANC) NMDA antagonists do not impair memory and have reduced behavioral performance effects compared to other classes of NMDA antagonists. Soc. Neurosci. 23: 1758.
16. 16. Black, M.A., R. Tremblay et al. 1995. N-Methyl-D-aspartate-or glutamate-mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR. J. Neurochem. 65: 2170-2177.
17. 17. Porter, R.H.P. & J.T. Greenamyre. 1995. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64: 614-623.
18. 18. Greene, J.G., R.H. Porter et al. 1996. ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp. Neurol. 137: 66-72.
19. 19. Monaghan, D.T. & H. Larsen. 1997. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J. Pharmacol. Exp. Ther. 280: 614-620.
20. 20. Small, D.L., M.O. Poulter et al. 1997. Alteration in NMDA receptor subunit mRNA expression in vulnerable and resistant regions of in vitro ischemic rat hippocampal slices. Neurosci. Lett. 232: 87-90.
21. 21. Gill, R., A. Bourson et al. 1998. Do excitatory amino acid receptors play a role in neuronal degeneration following acute stroke? In Glutamate Pharmacology Therapeutic Implications. International Business Communications. Southborough, MA.
22. 22. Blanpied, T.A., F.A. Boeckman et al. 1997. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77: 309-323.
23. 23. Black, M., T. Lanthorn et al. 1996. Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur. J. Pharmacol. 317: 377-381.
24. 24. Mealing, G.A.R., T.H. Lanthorn et al. 1997. Antagonism of N-methyl-D-aspartate-evoked currents in rat cortical cultures by ARL 15896AR. J. Pharmacol. Exp. Ther. 281: 376-383.
25. 25. Mealing, G.A.R., T.H. Lanthorn et al. 1999. Differences in the degree of trapping of low affinity uncompetitive NMDA receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. 288: 204-210.
26. 26. Subramanian, S., S.D. Donevan et al. 1996. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J. Pharmacol. Exp. Ther. 276: 161-168.
27. 27. Jones, S.M & M.A. Rogawski. 1992. The anticonvulsant (±)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI) selectively blocks NMDA-activated current in cultured rat hippocampal neurones: kinetic analysis and comparison with dizocilpine. Mol. Neuropharmacol. 2: 303-310.
28. 28. MacDonald, R.L. 1989. Antiepileptic drug action. Epilepsia 30(Suppl. 1): S19-S28.
29. 29. Hudzik, T.J, B.R. DeCosta et al. 1993. Sigma receptor mediated emetic responses in pigeons: agonists, antagonists and modifiers. Eur. J. Pharmacol. 236: 279-287.
30. 30. Bigot, D., A. Matus et al. 1991. Reorganization of the cytoskeleton in rat neurons following stimulation with excitatory amino acids in vitro. Eur. J. Neurosci. 3: 551-558.
31. 31. Faddis, B.T., M.J. Hasbani et al. 1997. Calpain activation contributes to dendritic remodeling after brief excitotoxic injury in vitro. J. Neurosci. 17: 951-959.
32. 32. Laferiere, N.B., R. Tremblay et al. 1999. AR-R 15896AR blocks the early NMDA-induced loss of MAP2 in primary cortical cultures. Neurol. Res. 21: 524-528.
33. 33. Giulian, D.L., J. Haverkamp et al. 1996. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16: 6021-6037.
34. 2+ entry into rat cerebellar granule cells in vitro. Soc. Neurosci. 24: 979.
35. 35. Johns, L., A.J. Sinclair et al. 1998. The effects of ARL 15896 on in vitro hypoxia/ hypoglycemia-induced amino acid release from rat cortical slices. Forum Eur. Neurosci. Poster # 33.25.
36. 36. Palmer, G.C., E.F. Cregan et al. 1995. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. J. Pharmacol. Exp. Ther. 274: 991-1000.
37. 37. Palmer, G.C., E.F. Cregan et al. 1995. Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann. N.Y. Acad. Sci. 576: 236-247.
38. 38. Cregan, E.F., J. Peeling et al. 1997. [(S)-Alpha-phenyl-2-pyridine-ethanamine dihydrochloride], a low affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia. J. Pharmacol. Exp. Ther. 283: 1412-1424.
39. 39. Preston, E., J. Webster et al. 1998. Lack of evidence for direct involvement of NMDA receptors or polyamines in blood-brain barrier injury after cerebral ischemia in rats. Brain Res. 813: 191-194.
40. 40. Buchan, A.M., D. Xue et al. 1992. A new model of temporary focal neocortical ischemia in the rat. Stroke 23: 273-279.
41. 41. Corbett, D. & S. Nurse. 1998. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog. Neurobiol. 54: 531-548.
42. 42. Sutherland, G.R., J.T. Perron et al. AR-R 15896AR reduces cerebral infarct volume following focal ischemia in cat. J. Stroke Cerebrovasc. Dis. In press.